Competitor Analysis: Targeted Therapy of Diabetes

Publisher: La Merie Publishing
Pages: 114
Format: PDF
Product Line:
Competitor Analysis
Version: Download file
Product Code: LMCA0028
Release Date: April of 2011

1,200.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Targeted Therapy of Diabetes

Product description

The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV inhibitors, GLP-1 analogs and SGLT inhibitors. Furthermore, emerging approaches for diabetes therapy are reported including glucokinase activators and 11beta-HSD1 inhibitors. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.


  • Rec Human Insulin for Injection (2nd Generation)
  • Biosimilar Rec Human Insulin for Injection (2nd Generation) in
  • Regulated Markets
  • Rhu Insulin (2nd Generation) in Off-Patent Countries: China
  • Rhu Insulin (2nd Generation) in Off-Patent Countries: Russia
  • Rhu Insulin (2nd Generation) in Off-Patent Countries: India
  • Rhu Insulin (2nd Generation) in Off-Patent Countries: Others
  • Modern Insulin Analogs (3rd Generation) for Injection
  • Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets
  • Tailored and Novel Insulin Analogs (4th Generation) for
  • Injection
  • Human Insulin with Drug Delivery for Injection
  • Other Long-Acting Insulin for Injection
  • Transgenic Human Insulin for Injection
  • Insulin/GLP-1 Combination Products
  • Inhaled Insulin
  • Oral Insulin
  • Transdermal Insulin
  • Others

PPAR Agonists

  • PPAR alpha Agonists
  • PPAR gamma Agonists / Insulin Sensitizer
  • PPAR alpha and gamma Agonists
  • PPAR delta Agonists
  • PPAR delta and gamma Agonists
  • PPAR alpha and delta Agonists
  • PPAR pan Agonists (alpha, gamma and delta)
  • Unspecified PPAR Agonists

Dipeptidyl peptidase-IV (DPP-IV) Inhibitors

  • GLP-1 Receptor Agonists
  • GLP-1 Analogs with Daily SC Injections
  • GLP-1 Analogs with Once Weekly SC Injections
  • GLP-1 Analogs with Bi-Weekly or Monthly SC Injections
  • Other GLP-1 Analogs for SC Injections
  • GLP-1 Analogs in Drug Delivery Formulations/Devices for
  • Parenteral Administration
  • GLP-1 Analogs in Drug Delivery Formulations for Oral
  • Administration
  • Oral Small Molecule GLP-1 Receptor Agonists
  • Dual Target GLP-1 Receptor Agonists / Combination Products
  • GLP-1 Analogs in Other, Non-Diabetes Indications

Sodium-Dependent Glucose Co-Transporter 2 (SGLT-2) Inhibitors

11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors

Glucokinase Activators (GKA)

Other Emerging Diabetes Drugs

  • Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists
  • Sirtuin (SIRT) Activators
  • Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors
  • Glucagon Receptor (GCGR) Antagonists
  • Glucocorticoid Receptor (GCGR) Antagonists
  • Novel Insulin Sensitizers
  • G-Protein Coupled Receptor 119 (GPR119) Agonists
  • Other Drugs Augmenting GLP-1 Secretion: GPR40, GPR120 & TGR5 Agonists
  • Other Glucometabolic Approaches
  • Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors
  • Other Metabolic Approaches
  • FGF-21-Receptor Agonists
  • Anti-Inflammatory Approaches
  • Induction of Immune Tolerance
  • Pancreatic Beta Cell Protection & Regeneration
  • Pancreatic Islet Cell Transplantation
  • Various Antidiabetic Approaches

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up